Ruxolitinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3697 publications

Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.

Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.

Journal: Leukemia & lymphoma

Published: April 15, 2026

Topical calcineurin inhibitors for atopic dermatitis are not associated with the development of subsequent lymphoma: A pharmacovigilance study using the FAERS database (2014-2025).

Topical calcineurin inhibitors for atopic dermatitis are not associated with the development of subsequent lymphoma: A pharmacovigilance study using the FAERS database (2014-2025).

Journal: JAAD international

Published: April 13, 2026

Keratin 16 inhibits type I interferon responses in differentiating keratinocytes of stressed and diseased skin.

Keratin 16 inhibits type I interferon responses in differentiating keratinocytes of stressed and diseased skin.

Journal: Science translational medicine

Published: April 08, 2026

Salvage nintedanib plus low-dose ruxolitinib therapy for bronchiolitis obliterans syndrome refractory to calcineurin inhibitors and glucocorticoids after allogeneic transplantation.

Salvage nintedanib plus low-dose ruxolitinib therapy for bronchiolitis obliterans syndrome refractory to calcineurin inhibitors and glucocorticoids after allogeneic transplantation.

Journal: Cell transplantation

Published: April 04, 2026

Nationwide survey of ruxolitinib administration for Japanese children with hemophagocytic lymphohistiocytosis.

Nationwide survey of ruxolitinib administration for Japanese children with hemophagocytic lymphohistiocytosis.

Journal: Pediatric hematology and oncology

Published: April 04, 2026

Association Between Topical Ruxolitinib Treatment and Psychiatric Outcomes in Adults With Vitiligo.

Association Between Topical Ruxolitinib Treatment and Psychiatric Outcomes in Adults With Vitiligo.

Journal: Journal of drugs in dermatology : JDD

Published: April 03, 2026

Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study.

Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study.

Journal: The Journal of dermatological treatment

Published: April 01, 2026

Localized granuloma annulare successfully treated with ruxolitinib.

Localized granuloma annulare successfully treated with ruxolitinib.

Journal: JAAD case reports

Published: March 30, 2026

Suppression of early pro-inflammatory senescent signature post-radiotherapy mitigates chronic bone damage.

Suppression of early pro-inflammatory senescent signature post-radiotherapy mitigates chronic bone damage.

Journal: bioRxiv : the preprint server for biology

Published: March 23, 2026

Topical Ruxolitinib for the Treatment of Hidradenitis Suppurativa.

Topical Ruxolitinib for the Treatment of Hidradenitis Suppurativa.

Journal: Skin therapy letter

Published: March 16, 2026

Recent developments in pharmacophore-based modeling of Ca2+/Calmodulin-dependent protein kinase II delta (CaMkIIδ) inhibitors for heart failure therapy.

Recent developments in pharmacophore-based modeling of Ca2+/Calmodulin-dependent protein kinase II delta (CaMkIIδ) inhibitors for heart failure therapy.

Journal: Expert opinion on drug discovery

Published: March 13, 2026

Fatal Triple-M Overlap Syndrome After Atezolizumab-Bevacizumab Therapy in Advanced Hepatocellular Carcinoma: A Case Report of Diagnostic Complexity and Therapeutic Escalation With Ruxolitinib.

Fatal Triple-M Overlap Syndrome After Atezolizumab-Bevacizumab Therapy in Advanced Hepatocellular Carcinoma: A Case Report of Diagnostic Complexity and Therapeutic Escalation With Ruxolitinib.

Journal: Cureus

Published: March 13, 2026

Showing 1-12 of 3,697

Last Updated: 04/28/2026